Results 51 to 60 of about 2,870,340 (221)

Evaluation of the Therapeutic Index of a Novel Phosphodiesterase 4B– Selective Inhibitor Over Phosphodiesterase 4D in Mice

Journal of Pharmacological Sciences, 2013
Phosphodiesterase 4 (PDE4) inhibitors have been developed for the treatment of pulmonary inflammatory diseases, but their clinical use was dose-limited by mainly gastric adverse effects.
Osamu Suzuki, Kiyoshi Mizukami, Maki Etori, Yoshitaka Sogawa, Nana Takagi, Hiroshi Tsuchida, Kiyoshi Morimoto, Taiji Goto, Toshiharu Yoshino, Tsuyoshi Mikkaichi, Kazuki Hirahara, Satoshi Nakamura, Hiroaki Maeda   +12 more
doaj   +1 more source

Women taking the “blue pill” (sildenafil citrate): such a big deal?

Drug Design, Development and Therapy, 2014
Giuseppe Lo Monte, Angela Graziano, Isabella Piva, Roberto Marci Department of Morphology, Surgery, and Experimental Medicine, University of Ferrara, Ferrara, Italy Abstract: For years, phosphodiesterase type 5 inhibitors have been used for the ...
Lo Monte G, Graziano A, Piva I, Marci R
doaj  

ENPP1, an Old Enzyme with New Functions, and Small Molecule Inhibitors—A STING in the Tale of ENPP1

Molecules, 2019
Ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1) was identified several decades ago as a type II transmembrane glycoprotein with nucleotide pyrophosphatase and phosphodiesterase enzymatic activities, critical for purinergic signaling. Recently,
Kenneth I. Onyedibe, Modi Wang, Herman O. Sintim   +2 more
doaj   +1 more source

The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue

Andrology, 2019
Erectile dysfunction (ED) is a relatively frequent disease that negatively impacts the overall quality of life, well‐being, and relationships. Although the use of phosphodiesterase 5 inhibitors (PDE5is) has revolutionized the treatment of ED, a high ...
A. Zucchi, Elisabetta Costantini, F. Scroppo, M. Silvani, Z. Kopa, E. Illiano, M. G. Petrillo, L. Cari, Giuseppe Nocentini   +8 more
semanticscholar   +1 more source

Tadalafil para o tratamento da hipertensão arterial pulmonar idiopática Tadalafil as treatment for idiopathic pulmonary arterial hypertension

Arquivos Brasileiros de Cardiologia, 2006
O uso de inibidores de fosfodiesterase, mais especificamente o sildenafil, no tratamento da hipertensão arterial pulmonar mostrou bons resultados, indicados por melhora dos parâmetros hemodinâmicos e da capacidade funcional.
Adriana Castro de Carvalho, André Luiz Hovnanian, Caio Julio César dos Santos Fernandes, Mônica Lapa, Carlos Jardim, Rogério Souza   +5 more
doaj   +1 more source

A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease

Haematologica, 2020
The most common treatment for patients with sickle cell disease (SCD) is the chemotherapeutic hydroxyurea, a therapy with pleiotropic effects, including increasing fetal hemoglobin (HbF) in red blood cells and reducing adhesion of white blood cells to ...
James G. McArthur, Niels Svenstrup, Chunsheng Chen, Aurelie Fricot, Caroline Carvalho, Julia Nguyen, Phong Nguyen, Anna Parachikova, Fuad Abdulla, Gregory M. Vercellotti, Olivier Hermine, Dave Edwards, Jean-Antoine Ribeil, John D. Belcher, Thiago T. Maciel   +14 more
doaj   +1 more source

Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility

Therapeutics and Clinical Risk Management, 2014
Eric G Katz,1 Ronny BW Tan,2 Daniel Rittenberg,1 Wayne J Hellstrom3 1Tulane University School of Medicine, New Orleans, LA, USA; 2Department of Urology, Tan Tock Seng Hospital, Singapore; 3Section of Andrology, Department of Urology, Tulane University ...
Katz EG, Tan RBW, Rittenberg D, Hellstrom WJ   +3 more
doaj  

Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations

International Journal of General Medicine, 2014
Bader Alsaikhan, Khalid Alrabeeah, Serge CarrierMcGill University Health Centre, Montreal, Quebec, QC, CanadaAbstract: Lower urinary tract symptoms (LUTS) and erectile dysfunction increase with age.
Alsaikhan B, Alrabeeah K, Carrier S
doaj  

A review of phosphodiesterase type 5 inhibitors

South African Family Practice, 2014
Currently, three phosphodiesterase type 5 (PDE5) inhibitors are available for clinical use in South Africa; sildenafil, vardenafil and tadalafil. The PDE inhibitors are used in males to treat erectile dysfunction.
N. Schellack, A. Agoro
doaj   +1 more source

Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review

Pulmonary Circulation, 2020
Pulmonary Hypertension due to left heart disease is the most common type of Pulmonary Hypertension. Morbidity and mortality significantly increase once Pulmonary Hypertension is present.
Galo M. Sanchez Palacios, Cindy Schmidt, Tammy Wichman   +2 more
doaj   +1 more source